125I-MIBG (Neoprobe/Childrens Cancer Group/CIS)

N/A

Report date: 2025/11/24 17:27:15
NME

Base Information

Drug Name125I-MIBG (Neoprobe/Childrens Cancer Group/CIS)
Drug Alias Name125I-MIBG
ClassificationSmall molecules > Heterocyclic drugsRadiation-emitting products > Nuclides > Iodine > 125IRadiation-emitting products > Radionuclide Drug Conjugates +[4] 
Mechanisms of ActionMitochondrial complex I (NADH dehydrogenase) inhibitorsDiagnostic imaging enhancers
TargetsMitochondrial complex I (NADH dehydrogenase)
Therapy Area/IndicationsNervous System Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesSun Pharmaceutical Industries Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesSun Pharmaceutical Industries IncNavidea Biopharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsNervous System Neoplasms

Other Information

ATC CodeN/A
Related LinksN/A